Compile Data Set for Download or QSAR
Report error Found 79 Enz. Inhib. hit(s) with all data for entry = 10561
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550415(3-(5-Isopropyl-2-methoxyphenyl)-1-methyl-4,6-dihyd...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550417(3-(5-Ethyl-2-methoxyphenyl)- 4,6-dihydropyrrolo[3,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550419(3-(4-(4-Methylpiperazin- 1-yl)phenyl)-4,6-dihydro-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550418(6-Chloro-N-((5-cyano-1,4,5,6-tetrahydropyrrolo[3,4...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550421(3-(1-(1-Methylpiperidin- 4-yl)-1H-pyrazol-4-yl)- 4...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550420(3-(4-Chloro-2- methoxyphenyl)-4,6- dihydropyrrolo[...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550423(3-(2-Methoxy-4-(1H- pyrazol-1-yl)phenyl)-4,6- dihy...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550422(3-(6-(4-Methylpiperazin- 1-yl)pyridin-3-yl)-4,6- d...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550425(3-(4-Morpholinophenyl)- 4,6-dihydropyrrolo[3,4- c]...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550424(3-(3-(4-Methylpiperazin- 1-yl)phenyl)-4,6- dihydro...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550427(3-(3-Methyl-4-(4- methylpiperazin-1- yl)phenyl)-4,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550426(3-(2-Fluoro-4-(4- methylpiperazin-1- yl)phenyl)-4,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550429(3-(3-(2-Oxopyrrolidin-1- yl)phenyl)-4,6- dihydropy...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550428(3-(3-(2-Oxooxazolidin-3- yl)phenyl)-4,6- dihydropy...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550399(3-(6-Methoxypyridin-3- yl)-4,6-dihydro- pyrrolo[3,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550398(5-(5-Cyano-1,4,5,6- tetrahydropyrrolo[3,4- c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550401(3-(5-Fluoro-2- isopropoxyphenyl)-4,6- dihydropyrro...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550400(3-(5-Cyano-1,4,5,6- tetrahydropyrrolo[3,4- c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550403(3-(6-Isopropoxypyridin- 3-yl)-4,6- dihydropyrrolo[...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550402(N-Benzyl-4-(5-cyano- 1,4,5,6- tetrahydropyrrolo[3,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550405(3-(1-Methyl-1H-indazol- 5-yl)-4,6- dihydropyrrolo[...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550404(3-(4-(4-Methylpiperazine- 1-carbonyl)phenyl)-4,6- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550407(3-(5-Methyl-1H-indazol- 4-yl)-4,6- dihydropyrrolo[...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550409(N-(3-(5-Cyano-1,4,5,6- tetrahydropyrrolo[3,4- c]py...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550408(3-(5-Cyano-1,4,5,6- tetrahydropyrrolo[3,4- c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550411(3-(2-Fluorophenyl)-4,6- dihydropyrrolo[3,4-c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550410(US11306096, Example 57)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550413(3-(2-fluoro-5-methylphenyl)-1-methyl-4,6-dihydropy...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550412(3-(4-Fluorophenyl)-4,6- dihydropyrrolo[3,4-c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550430(3-(5-Chloro-2- methoxyphenyl)-4,6- dihydropyrrolo[...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550432(N-Benzyl-4-(5-cyano-1,4,5,6-tetrahydropyrrolo[3,4-...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550356(1-(4-Fluorophenyl)-4,6- dihydropyrrolo[3,4-c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550359(1-(Quinolin-3-yl)-4,6- dihydropyrrolo[3,4-c]pyrazo...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550361(1-(1-Phenyl-1H-pyrazol-4-yl)- 4,6-dihydropyrrolo[3...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550383(US11306096, Example 30)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550377(US11306096, Example 29 | 1-Benzyl-3-phenyl-4,6- di...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550385(1-Benzyl-3-(isoquinolin-3-ylamino)-4,6-dihydropyrr...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550384(3-(Isoquinolin-3-ylamino)-4,6-dihydropyrrolo[3,4-c...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550387(N-((5-Cyano-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazo...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550388(N-((5-Cyano-1-phenyl-1,4,5,6-tetrahydropyrrolo[3,4...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550391(3-(3-Cyanophenyl)-4,6- dihydropyrrolo[3,4- c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550390(3-(4-(Benzyloxy)phenyl)- 4,6-dihydropyrrolo[3,4- c...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550395(3-(4-Cyanophenyl)-4,6- dihydropyrrolo[3,4- c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550394(3-(4-Phenoxyphenyl)-4,6- dihydropyrrolo[3,4- c]pyr...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550397(3-(2-Chloro-5-(trifluoro- methoxy)phenyl)- 4,6-dih...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550396(3-(2-Fluoro-4- (trifluoromethyl)phenyl)- 4,6-dihyd...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550366(3-(5-Cyano-5,6-dihydropyrrolo[3,4- c]pyrazol-1(4H)...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550369(4-(5-Cyano-3-methyl-5,6-dihydropyrrolo[3,4-c]pyraz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550370(1-(1-Methyl-1H-indazol-5-yl)- 4,6-dihydropyrrolo[3...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM550372(1-(1H-Indazol-3-yl)-4,6- dihydropyrrolo[3,4-c]pyra...)
Affinity DataIC50: 1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 79 total ) | Next | Last >>
Jump to: